Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerofe with or without Doxorubicin in AML and High Risk MDS
NCT03059615Phase 2Withdrawn
- Sponsor
- Immune System Key Ltd.
- Start
- Oct 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nerofe in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Immune System Key Ltd.. Planned start Oct 2018; status: withdrawn.
02
Drugs
nerofe
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03059615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03059615.